Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Osteosarcoma 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 16Doxorubicin 13pembrolizumab 11Temozolomide 11X-Rays 10Radiation 10atezolizumab 8Radiotherapy 8Irinotecan 8Phantoms, Imaging 7Nivolumab 7fludarabine 6Vincristine 6Immunoglobulin G 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5cemiplimab 5cabozantinib 5Sirolimus 5Ifosfamide 5Gemcitabine 5Disulfides 5palbociclib 4olaparib 4fludarabine phosphate 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blood Component Removal × Sarcoma × 30 days × Clear all
NCT07428993 2026-05-19

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

St. Jude Children's Research Hospital

Phase 2 Recruiting
41 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡